Health
Combo monoclonal antibody drugs may lower coronavirus loads – CIDRAP
Bamlanivimab paired with etesevimab was more effective than bamlanivimab alone.
Mildly to moderately ill COVID-19 adult outpatients given a combination of the monoclonal antibodies bamlanivimab and etesevimab early in the disease had significantly lower viral loads at day 11 than those who received a placebo, but a similar effect was not seen in those given bamlanivimab alone, a study published today in JAMA finds.
Bamlanivimab manufacturer Eli Lilly sponsored the double-blind phase 2/3 BLAZE-1 clinical trial, which involved 533 COVID-19 patients at 49 US medical centers. The…
-
General11 hours agoVictorian school teacher charged with soliciting child abuse material
-
Business20 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business22 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
Business19 hours agoHere’s what analysts expect for the BHP share price in the coming year